FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) has completed enrollment for the pivotal phase of the Gore ASSURED Clinical Study. This investigational device exemption (IDE) ...
Gore ASSURED Clinical Study results through 36 months demonstrate 100 percent closure success * with the GORE ® CARDIOFORM ASD Occluder, and consistent safety outcomes † across a broad range of ASD ...
FLAGSTAFF, Arizona, Oct. 2, 2019 /PRNewswire/ -- W. L. Gore & Associates (Gore) has introduced the newest member of its family of occluders, the GORE® CARDIOFORM ASD Occluder, which has received CE ...
CAUTION: Investigational device. Limited by United States law to investigational use. The Gore RELIEF Clinical Study is evaluating the safety and efficacy of transcatheter closure of patent foramen ...
FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) announces positive results from its REDUCE Study assessing closure of patent foramen ovale (PFO) for the reduction of recurrent ...
FLAGSTAFF, Ariz.- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder for the percutaneous closure of ...
FLAGSTAFF, Ariz., April 3, 2018 /PRNewswire/ -- Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W.
FLAGSTAFF, Ariz. Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W. L. Gore & Associates, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results